Nebulizers — fill volume, residual volume and matching of nebulizer to compressor  by Kendrick, A.H. et al.
Respiratory Medicine (1995) 89, 157-l 59 
Editorial 
Nebulizers - fill volume, residual volume and matching 
of nebulizer to compressor 
Introduction 
Nebulizers are used routinely as part of the man- 
agement of a wide variety of respiratory problems, 
most commonly to administer anti-cholinergic and 
&agonist drugs. More recently, they have been used 
for aerosol administration of deoxyribonuclease in 
the treatment of cystic fibrosis, and more viscous 
drugs such as pentamidine for prophylaxis against 
Pneumocystis pneumonia in patients infected with 
the HIV virus. Nebulizer systems are now in common 
use, but we still do not fully understand the func- 
tional operation of these systems. The effects of 
evaporation of the diluent and drug, and whether the 
speed of delivery of the drug to the patient plays a 
key role on the efficacy of drug therapy by this mode, 
are not fully-evaluated. Whilst these pose interesting 
problems, there remain a number of everyday prac- 
tical problems which can easily be addressed. Effec- 
tive delivery of any aerosol is important to provide 
maximum possible benefit to the patient. In particu- 
lar, the actual volume of solution - the fill volume - 
used for nebulization and the importance of the 
correct matching of the nebulizer and compressor for 
ward or domiciliary use, need to be taken into 
account. 
Fii Volume and Residual Volume 
Each nebulizer chamber has a residual volume in 
which a small amount of drug and diluent will remain 
when the nebulizer has run ‘dry’. The consequence of 
this is that the amount of drug nebulized is less than 
the amount initially placed in the chamber. Thus, if 
a 2.5 ml ampoule of drug is placed in a nebulizer 
chamber with a residual volume of 1.75 ml, only 
0.75 ml of the solution is actually available to the 
patient, whereas, if a chamber with a 0.5 ml residual 
volume is used, 2 ml of solution is available. Simply 
increasing the fill volume, to say 4 ml, would increase 
the volume of respirable solution available to the 
patient, but has the drawbacks of increased cost 
and inefficiency, and will prolong the total time of 
nebulization. 
In 1983, when Clay et al. (1) made their recommen- 
dation of a 4 ml fill volume for bronchodilator drugs, 
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Fig. I ElTect on bronchodilator drug output of increasing 
the fill volume from 2.5 ml to 4ml on the Sidestream 
nebulizer, under simulated tidal breathing using compressed 
air to drive the nebulizer. The residual volume is 0.5 ml. For 
a fill volume of 2.5 ml, the nebulization time to ‘dryness’ 
was 6min, which increased to 10 min using a 4 ml fill 
volume. This 70% increase in nebulization time increased 
drug output by only 12%. Data from reference (3). Solid line 
(X), 2.5 ml volume; dashed line ( q ), 4 ml volume. 
no nebulizer chambers existed with a residual volume 
of less than 1 ml. A similar recommendation has been 
made for antibiotic drugs (2). Consequently, many 
protocols call for a fill volume of 4 ml in the nebu- 
lizer. These recommendations are based on nebulizer 
chambers which have a residual volume of 1 ml or 
more. Since then, a number of new nebulizer cham- 
bers have become available that have a residual 
volume of less than 1 ml, and therefore do not need 
to have iill volumes of 4 ml. 
The effects of increasing the fdl volume are shown 
in Figs 1 and 2. Where there is a large residual 
volume, the percentage of drug delivered to the 
patient will increase with increased fill volume if 
nebulization continues to dryness. However, for most 
nebulizers with a small residual volume, the percent- 
age increase is less than 25% for either broncho- 
dilator drugs (3) or antibiotics (4). Whilst this 
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Fig. 2 Effect on antibiotic drug output, by percentage 
mass, of increasing fill volume from 2.5 ml to 4 ml in 14 
nebulizers with differing residual volumes. (a) The open bar 
shows the drug output at a 2.5 ml fill volume, and the solid 
bar shows the percentage increase in drug output when the 
fill volume is increased to 4 ml. Systems with a small 
residual volume (Sidestream, Micro-Cirrus) show approxi- 
mately 20% increase in output, whereas systems with larger 
residual volumes (Unineb, Ava-Neb, Aeromist, Up-Draft) 
show a considerably greater increase in the percentage of 
drug delivered. (b) The effect of increasing fill volume 
on nebulization time for each nebulizer. Some systems 
(Up-Draft II, Micro-Cirrus, Venticare) show a 50% or 
greater increase in nebulization time. Data from reference 
(4). 
increased drug delivery may be of benefit to the 
patient, poorer compliance may possibly occur 
because of the inherently longer nebulization times 
required. 
The fill volume does not appear to influence the 
particle size distribution. Particle size should ideally 
be 3,~rn-5,~rn to achieve effective lung deposition. 
The flow-rate and pressure of gas from the com- 
pressor are positively correlated, so the higher the 
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Fig. 3 Relation of mass median aerodynamic diameter 
(MMAD) and flow-rate for 23 nebulizerkompressor com- 
binations using a fill volume of 2.5 ml and 5 ml. There was 
no significant difference between the relations at 2.5 ml and 
5 ml, so MMAD is independent of fill volume. Data from 
reference (5). Solid line (X), 2.5 ml volume; dashed line (0) 
5 ml volume. 
pressure, the higher the flow-rate at the nebulizer (5). 
The higher the flow-rate at the nebulizer, the smaller 
the particle size of the aerosol will be. To compare 
different systems, the mass median aerodynamic 
diameter (MMAD) is calculated. This is the particle 
diameter above which 50% of the mass of the aerosol 
particles is distributed. Comparing the MMAD at a 
fill volume of 2.5 ml and at 5 ml, the relationship of 
MMAD to flow-rate is not significantly different 
(Fig. 3). Therefore, choosing a higher fill volume will 
not significantly increase the effective deposition of 
aerosol particles. 
Drug companies now supply bronchodilator drugs 
in ampoule sizes of 2 ml or 2.5 ml. To our knowledge, 
there is no evidence to show that increasing the fill 
volume to 4 ml, either subjectively or objectively, 
improves the quality of life of the patient. The 
practice of adding diluent to the nebulizer solution 
from these ampoules, may well further decrease the 
compliance with therapy. Furthermore, adding saline 
increases the overall costs of drug therapy with the 
additional need for saline, needles and syringes. This 
leads to more potential needle-stick injuries for both 
patients and healthcare workers, and increased staff 
costs when this practice is used in health centres or 
hospital units. 
In conclusion, the view that the fill volume of 
nebulizers should be 4 ml is not supported by current 
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Fig 4 Relation of MMAD for a 2.5 ml fill volume for 6 
compressors using the Cirrus nebulizer. The compressors 
were Aeroneb Standard, Aeroneb High Power, Medix 2000, 
Medix Traveller, Medix Minor and Novair II. The two 
Aeronebs had the lower flow-rates. Data from reference (5). 
evidence regarding nebulizer performance, for 
either bronchodilator drugs or antibiotics. This is 
particularly true when using the newer nebulizer 
chambers that have a residual volume of less than 
1 ml. The increased nebulization time, additional 
staff and consumable costs simply do not justify 
using a 4 ml volume as a routine. We therefore 
recommend that the nebulizers in routine use should 
have as small a residual volume as possible, that users 
should know what this volume is, and that a fill 
volume of no less than 2 ml should be used. This does 
not preclude the use of chambers with larger residual 
volumes, but these should be reserved for cases where 
larger volumes of drugs need to be nebulized. 
Matching Nebulizer to Compression 
There are a wide variety of compressors and nebu- 
lizer chambers available, which have recently been 
reviewed (5). Each compressor and each nebulizer 
has its own characteristics, so simply combining any 
nebulizer chamber with any compressor may not 
provide the optimum performance characteristics, 
and hence the greatest benefit to the patient. The 
importance of correct matching has been described 
before (6), but the message does not appear to have 
reached many users in hospitals, family practices 
and the community, and certainly has not reached 
hospital supplies departments. 
The effects of different compressors on the same 
nebulizer chamber, under the same experimental con- 
ditions is shown in Fig. 4. The two compressors with 
the lowest flow-rate at the nebulizer, generate an 
MMAD which exceeds the maximum recommended 
level of Sprn. At the higher flow-rates, the MMAD 
decreases to within acceptable levels. Thus, for the 
Cirrus nebulizer to produce particles of less than 
Spurn, a flow-rate at the nebulizer of at least 
6 1 min - ’ is required. 
The importance of matching nebulizers with com- 
pressors cannot be understated. More education of 
all health care workers is needed. Furthermore, sup- 
plies departments should consult with local experts 
and manufacturers to ensure that when they purchase 
nebulizer chambers and compressors, they are 
matched, thus providing optimum treatment for the 
patient. 
A. H. KENDRICK*, E. C. SMITH* AND J. DENYER~ 
*Respiratory Department 
Bristol Royal Infirmary, Bristol 
and TMedic-Aid, Pagham, Sussex, U.K. 
References 
1. 
2. 
3. 
4. 
5. 
6. 
Clay MM, Pavia D, Newman SP, Lennard-Jones T, 
Clarke SW. Assessment of iet nebulizers for lung aerosol 
therapy. Lancet 1983; 2: 542-594. 
Smye SW, Shaw A, Norwood HM, Littlewood JM. 
Some factors effecting the efficiency of a jet nebulizer 
system. Clin Phys Physiol Meas 1990; 11: 167-175. 
Denver J. Dvche T. Smith EC. Kendrick AH. The 
opt&urn ‘volime fo; nebulization of bronchodilators. 
Ear Respir J 1993; 6 (suppl 17): 148s. 
Hurley PK, Smye SW, Cunliffe H. Assessment of antibi- 
otic aerosol generation using commercial jet nebulizers. 
J Aerosol Med 1994; 7: 217-228. 
Smith EC, Denyer J, Kendrick AH. Comparison of 
twenty-three nebulizer/compressor combinations for 
domiciliary use. Ear Respir J submitted. 
Steventon RD, Wilson RDE. A guide to apparatus for 
home nebulization therapy. Allen Hanburys Ltd, 1986. 
